Skip to main content
. 2010 Oct-Dec;2(4):356–361. doi: 10.4103/0975-1483.71623

Figure 3.

Figure 3

Comparative IOP-lowering activity. -Δ-Niosomal formulation. -▲-Pure drug solution -▲- Liposomal formulation